search
Back to results

ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES (SOCRATES)

Primary Purpose

Aortic Aneurysm, Abdominal

Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
ESAR treatment: Endograft + Heli-FX Endoanchor
FEVAR treatment : Fenestrated endograft
Sponsored by
FCRE (Foundation for Cardiovascular Research and Education)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Aortic Aneurysm, Abdominal

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subject is >18 years old
  • Subject is scheduled for primary treatment of the abdominal aortic aneurysm with a non-aneurysmal infrarenal aortic sealing zone proximal to the aneurysm that is sufficiently healthy for a proximal neck length that is at least 4mm and not more than15 mm and has a circumferential minimum sealing zone length of 8 mm
  • Subject is not a candidate for safe and effective standard EVAR
  • Subject is able and willing to comply with the protocol and to adhere to the follow-up requirements.
  • Subject has provided written informed consent
  • Subject is an eligible candidate according to the Endurant II/IIs + Heli-FX EndoAnchor, Cook Zenith Fenestrated Graft, and Terumo Fenestrated Anaconda Instructions For Use
  • Aortic neck diameter from 19 to 31mm
  • Iliac diameters with a range from 9 to 21mm
  • Infrarenal neck angulation ≤45°
  • Distal fixation length(s) of ≥30mm

Exclusion Criteria:

  • Subject is participating in a concurrent study which may confound study results
  • Subject has a life expectancy <2 year
  • Subject is female of childbearing potential in whom pregnancy cannot be excluded
  • Subject with eGFR <30 mL/min/m2 (KDOQI classification - exclude class IV and above) and or on dialysis
  • Subject with a MI or CVA within 3 months prior to index procedure
  • Subject with known Connective Tissue Disease
  • Subject has a known hypersensitivity or contraindication to anticoagulants, antiplatelets, or contrast media, which is not amenable to post-treatment
  • Subject who has undergone prior endovascular or open surgical treatment for abdominal aortic aneurysm
  • Subject requires emergent aneurysm treatment, for example, trauma or rupture
  • Subject has a known hypersensitivity or allergies to study device implant material
  • Subject has an aneurysm that is:

    • Suprarenal, pararenal, or thoracoabdominal
    • Mycotic
    • Inflammatory
    • Pseudoaneurysm
  • Subject is presenting with thrombus or calcification of the proximal aneurysm neck: circumferential >50%
  • Pre-op stenosis of the renal arteries > 50%
  • Subject has active infection or history of COVID-19. History of COVID-19 is defined as availability of positive COVID-19 test with sequelae or hospitalization for treatment of COVID-19.

Sites / Locations

  • Hospital Ottakring, Institute for Vascular SurgeryRecruiting
  • CRC thoracic Vascular Surgery, ZOL GenkRecruiting
  • Universitair Ziekenhuis Gent, Thoracale en vasculaire heelkundeRecruiting
  • Amrois Paré Hospital (APHP)Recruiting
  • Service de Chirurgie Vasculaire et Endovasculaire CHU Gabriel-Montpied 58 rue MontalembertRecruiting
  • Hospices Civils de lyon - Hôpital Edouard HerriotRecruiting
  • Centre Hospitalier Universitaire de RennesRecruiting
  • University Hospital RWTH AachenRecruiting
  • University Hospital LeipzigRecruiting
  • University Hospital LMU Munich
  • Martin Austermann
  • University Hospital Regensburg
  • University of Bologna, IRCCS S. Orsola Hospital,Recruiting
  • IRCCS Ospedale San Raffaele, Chirurgia VascolareRecruiting
  • Vascular Endovascular Surgery University of Perugia;
  • VUMC Amsterdam
  • Catharina Ziekenhuis
  • Hospital Ramon Y CajalRecruiting
  • Hospital Universitario DonostiaRecruiting
  • Inselspital Bern, Universitätsklinik für Gefässchirurgie

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

ESAR

FEVAR

Arm Description

Endovascular Aneurysm Repair + Heli-FX EndoAnchors

Fenestrated EndoVascular Aneurysm Repair

Outcomes

Primary Outcome Measures

Effectiveness Endpoint - Technical Success
Composite of technical success at index procedure, and freedom from type IA or type III endoleak, freedom from aneurysm related mortality (ARM), and freedom from secondary reinterventions through 12 months post index procedure.
Safety Endpoint - Freedom from Major Adverse Events
Freedom from MAE through 30 days post index procedure. MAE defined as: All-Cause-Mortality, Bowel Ischemia, Myocardial Infraction, Procedural Blood Loss > 1000cc, Access related complications, permanent paraplegia and paraparesis at 30 days, disabling stroke, respiratory failure, or renal complications

Secondary Outcome Measures

Total contrast volume (ml) at index procedure
Total contrast volume (mL) at index procedure
Total fluoroscopy time (minutes) at index procedure
Total fluoroscopy time (minutes) at index procedure
Duration (minutes) of index procedure
3. Duration (minutes) of index procedure (time between initial skin access to final closure of the last artery access site)
Adequate penetration of endo anchors as accessed by the Core Lab
Adequate penetration of endo anchors as accessed by the Core Lab
Clinical success
7. Clinical success defined as technical success + freedom from intra-operative death and freedom from type IA/III endoleak in the first post-op image within 30 days.
Visceral artery patency or occlusion at 1, 12, 24 and 36 months follow-up
Visceral artery patency or occlusion at 1, 12, 24 and 36 months follow-up
Freedom from type Ia and III endoleaks at 1, 12, 24 and 36 months follow-up
Freedom from type Ia and III endoleaks at 1, 12, 24 and 36 months follow-up
Freedom from aneurysm related secondary reinterventions at 1, 12, 24 and 36 months follow-up
Freedom from aneurysm related secondary reinterventions at 1, 12, 24 and 36 months follow-up
Freedom from aneurysm related mortality at 1, 12, 24 and 36 months follow-up
Freedom from aneurysm related mortality at 1, 12, 24 and 36 months follow-up
Freedom from stent graft migration (>10mm change from 1-month follow-up imaging) at 12, 24 and 36 months follow-up
Freedom from stent graft migration (>10mm change from 1-month follow-up imaging) at 12, 24 and 36 months follow-up
Sac dynamics (>5mm change from 1-month follow-up imaging): increase, stable, decrease at 12, 24, and 36 months follow-up
Sac dynamics (>5mm change from 1-month follow-up imaging): increase, stable, decrease at 12, 24, and 36 months follow-up
Freedom from conversion to open repair at 1, 12, 24 and 36 months follow-up
Freedom from conversion to open repair at 1, 12, 24 and 36 months follow-up
Freedom from AAA rupture at 1, 12, 24 and 36 months follow-up
Freedom from AAA rupture at 1, 12, 24 and 36 months follow-up
Overall SCI rate, include transient events at 1 and 12 months follow-up
Overall SCI rate, include transient events at 1 and 12 months follow-up
Freedom from aortic neck-related secondary interventions
reinterventions for Type IAa endoleak, migration of the proximal stent graft, and progression of disease in the infrarenal aortic neck; progression of disease is defined as enlargement of the infrarenal aortic neck compared to the first postprocedural CT scan, as measured by either diameter, surface and/or volume.

Full Information

First Posted
July 22, 2020
Last Updated
March 15, 2023
Sponsor
FCRE (Foundation for Cardiovascular Research and Education)
Collaborators
Medtronic
search

1. Study Identification

Unique Protocol Identification Number
NCT04503395
Brief Title
ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES
Acronym
SOCRATES
Official Title
Physician Initiated Trial Investigating ESAR (EVAR Plus Heli-FX EndoAnchors) and FEVAR for the Treatment of Aortic Aneurysms With Short Infrarenal Aortic Neck
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 21, 2021 (Actual)
Primary Completion Date
June 1, 2026 (Anticipated)
Study Completion Date
June 1, 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
FCRE (Foundation for Cardiovascular Research and Education)
Collaborators
Medtronic

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aim of this randomized study is to compare the safety and performance of EndoVascular Aneurysm Repair with ESAR using Endurant + Heli-FX™ EndoAnchor™ system and FEVAR using customizable grafts from Cook (Zenith Fenestrated Graft) and Terumo (Fenestrated Anaconda Graft) for the treatment of aortic aneurysms with short aortic neck (4 to 15mm).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Aortic Aneurysm, Abdominal

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
comparision of two different procedure to repair abdominal aortic aneurysms with short necks
Masking
None (Open Label)
Allocation
Randomized
Enrollment
204 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ESAR
Arm Type
Experimental
Arm Description
Endovascular Aneurysm Repair + Heli-FX EndoAnchors
Arm Title
FEVAR
Arm Type
Active Comparator
Arm Description
Fenestrated EndoVascular Aneurysm Repair
Intervention Type
Device
Intervention Name(s)
ESAR treatment: Endograft + Heli-FX Endoanchor
Intervention Description
ESAR treatment: Endurant II or Endurant IIs endograft + Heli-FX Endoanchor
Intervention Type
Device
Intervention Name(s)
FEVAR treatment : Fenestrated endograft
Intervention Description
Cook Zenith Fenestrated Graft or the Terumo Fenestrated Anaconda Graft
Primary Outcome Measure Information:
Title
Effectiveness Endpoint - Technical Success
Description
Composite of technical success at index procedure, and freedom from type IA or type III endoleak, freedom from aneurysm related mortality (ARM), and freedom from secondary reinterventions through 12 months post index procedure.
Time Frame
through 12 months post-procedure
Title
Safety Endpoint - Freedom from Major Adverse Events
Description
Freedom from MAE through 30 days post index procedure. MAE defined as: All-Cause-Mortality, Bowel Ischemia, Myocardial Infraction, Procedural Blood Loss > 1000cc, Access related complications, permanent paraplegia and paraparesis at 30 days, disabling stroke, respiratory failure, or renal complications
Time Frame
through 30 days post-procedure
Secondary Outcome Measure Information:
Title
Total contrast volume (ml) at index procedure
Description
Total contrast volume (mL) at index procedure
Time Frame
at index procedure
Title
Total fluoroscopy time (minutes) at index procedure
Description
Total fluoroscopy time (minutes) at index procedure
Time Frame
at index procedure
Title
Duration (minutes) of index procedure
Description
3. Duration (minutes) of index procedure (time between initial skin access to final closure of the last artery access site)
Time Frame
at index procedure
Title
Adequate penetration of endo anchors as accessed by the Core Lab
Description
Adequate penetration of endo anchors as accessed by the Core Lab
Time Frame
at index procedure
Title
Clinical success
Description
7. Clinical success defined as technical success + freedom from intra-operative death and freedom from type IA/III endoleak in the first post-op image within 30 days.
Time Frame
through 30 days post-procedure
Title
Visceral artery patency or occlusion at 1, 12, 24 and 36 months follow-up
Description
Visceral artery patency or occlusion at 1, 12, 24 and 36 months follow-up
Time Frame
through 1,12,24 and 36-months post-op
Title
Freedom from type Ia and III endoleaks at 1, 12, 24 and 36 months follow-up
Description
Freedom from type Ia and III endoleaks at 1, 12, 24 and 36 months follow-up
Time Frame
through 1,12,24 and 36-months post-op
Title
Freedom from aneurysm related secondary reinterventions at 1, 12, 24 and 36 months follow-up
Description
Freedom from aneurysm related secondary reinterventions at 1, 12, 24 and 36 months follow-up
Time Frame
through 1,12,24 and 36-months post-op
Title
Freedom from aneurysm related mortality at 1, 12, 24 and 36 months follow-up
Description
Freedom from aneurysm related mortality at 1, 12, 24 and 36 months follow-up
Time Frame
through 1,12,24 and 36-months post-op
Title
Freedom from stent graft migration (>10mm change from 1-month follow-up imaging) at 12, 24 and 36 months follow-up
Description
Freedom from stent graft migration (>10mm change from 1-month follow-up imaging) at 12, 24 and 36 months follow-up
Time Frame
through 12,24 and 36-months post-op
Title
Sac dynamics (>5mm change from 1-month follow-up imaging): increase, stable, decrease at 12, 24, and 36 months follow-up
Description
Sac dynamics (>5mm change from 1-month follow-up imaging): increase, stable, decrease at 12, 24, and 36 months follow-up
Time Frame
through 12,24 and 36-months post-op
Title
Freedom from conversion to open repair at 1, 12, 24 and 36 months follow-up
Description
Freedom from conversion to open repair at 1, 12, 24 and 36 months follow-up
Time Frame
through 1,12,24 and 36-months post-op
Title
Freedom from AAA rupture at 1, 12, 24 and 36 months follow-up
Description
Freedom from AAA rupture at 1, 12, 24 and 36 months follow-up
Time Frame
through 1,12,24 and 36-months post-op
Title
Overall SCI rate, include transient events at 1 and 12 months follow-up
Description
Overall SCI rate, include transient events at 1 and 12 months follow-up
Time Frame
through 1 and 12 months post-op
Title
Freedom from aortic neck-related secondary interventions
Description
reinterventions for Type IAa endoleak, migration of the proximal stent graft, and progression of disease in the infrarenal aortic neck; progression of disease is defined as enlargement of the infrarenal aortic neck compared to the first postprocedural CT scan, as measured by either diameter, surface and/or volume.
Time Frame
at 1-, 12-, 24- and 36-months follow-up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject is >18 years old Subject is scheduled for primary treatment of the abdominal aortic aneurysm with a non-aneurysmal infrarenal aortic sealing zone proximal to the aneurysm that is sufficiently healthy for a proximal neck length that is at least 4mm and not more than15 mm and has a circumferential minimum sealing zone length of 8 mm Subject is not a candidate for safe and effective standard EVAR Subject is able and willing to comply with the protocol and to adhere to the follow-up requirements. Subject has provided written informed consent Subject meets the other anatomical requirements according to the locally applicable Endurant II/IIs stent graft system, Heli-FX EndoAnchor system, Terumo Fenestrated Anaconda (available in EU only) and/or Cook Zenith Fenestrated Graft Instructions for Use Proximal neck length of the aorta within 4-15mm and a minimum circumferential sealing zone of 8mm Aortic neck diameter from 19 to 31mm Infrarenal neck angulation ≤45° Exclusion Criteria: Subject is participating in a concurrent study which may confound study results Subject has a life expectancy <2 year Subject is female of childbearing potential in whom pregnancy cannot be excluded Subject with eGFR <30 mL/min/m2 (KDOQI classification - exclude class IV and above) and or on dialysis Subject with a MI or CVA within 3 months prior to index procedure Subject with known Connective Tissue Disease Subject has a known hypersensitivity or contraindication to anticoagulants, antiplatelets, or contrast media, which is not amenable to post-treatment Subject who has undergone prior endovascular or open surgical treatment for abdominal aortic aneurysm Subject requires emergent aneurysm treatment, for example, trauma or rupture Subject has a known hypersensitivity or allergies to study device implant material Subject has an aneurysm that is: Suprarenal, pararenal, or thoracoabdominal Mycotic Inflammatory Pseudoaneurysm Subject is presenting with thrombus or calcification of the proximal aneurysm neck: circumferential >50% Pre-op stenosis of the renal arteries > 50% Subject has active infection or history of COVID-19. History of COVID-19 is defined as availability of positive COVID-19 test with sequelae or hospitalization for treatment of COVID-19.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Annelena Held-Wehmöller, PhD
Phone
+49 15785128140
Email
info@fcre.eu
First Name & Middle Initial & Last Name or Official Title & Degree
Sarah Litterscheid
Phone
+49 15785319015
Email
sarah.litterscheid@fcre.eu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Giovanni Torsello, Prof. Dr.
Organizational Affiliation
Vascupedia
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Brant Ullery, MD, MBA
Organizational Affiliation
Medical Director, Vascular Surgery Providence Heart and Vascular Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Ottakring, Institute for Vascular Surgery
City
Vienna
ZIP/Postal Code
1160
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Afshin Assadian
Facility Name
CRC thoracic Vascular Surgery, ZOL Genk
City
Genk
ZIP/Postal Code
3600
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wouter Lansink, Dr MD
Facility Name
Universitair Ziekenhuis Gent, Thoracale en vasculaire heelkunde
City
Gent
ZIP/Postal Code
9000
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Isabelle vanHerzeele
Facility Name
Amrois Paré Hospital (APHP)
City
Boulogne
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Raphael Coscas
Facility Name
Service de Chirurgie Vasculaire et Endovasculaire CHU Gabriel-Montpied 58 rue Montalembert
City
Clermont Ferrand
ZIP/Postal Code
63003
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fabien Thaveau
Facility Name
Hospices Civils de lyon - Hôpital Edouard Herriot
City
Lyon
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Antoine Millon
Facility Name
Centre Hospitalier Universitaire de Rennes
City
Rennes
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Adrien Kaladji
Facility Name
University Hospital RWTH Aachen
City
Aachen
ZIP/Postal Code
52074
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Drosos Kotelis
Facility Name
University Hospital Leipzig
City
Leipzig
ZIP/Postal Code
04109
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dierk Scheinert
Facility Name
University Hospital LMU Munich
City
Munich
ZIP/Postal Code
81337
Country
Germany
Individual Site Status
Suspended
Facility Name
Martin Austermann
City
Münster
ZIP/Postal Code
48145
Country
Germany
Individual Site Status
Active, not recruiting
Facility Name
University Hospital Regensburg
City
Regensburg
ZIP/Postal Code
93053
Country
Germany
Individual Site Status
Suspended
Facility Name
University of Bologna, IRCCS S. Orsola Hospital,
City
Bologna
ZIP/Postal Code
40138
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mauro Gargiulo, Prof
Facility Name
IRCCS Ospedale San Raffaele, Chirurgia Vascolare
City
Milano
ZIP/Postal Code
20132
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrea Kahlberg, Prof
Facility Name
Vascular Endovascular Surgery University of Perugia;
City
Perugia
ZIP/Postal Code
06100
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Massimo Lenti, Prof MD
First Name & Middle Initial & Last Name & Degree
Giacomo Isernia, MD, PHD
Facility Name
VUMC Amsterdam
City
Amsterdam
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kak Khee Yeung
Facility Name
Catharina Ziekenhuis
City
Eindhoven
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Philippe Cuypers
Facility Name
Hospital Ramon Y Cajal
City
Madrid
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrés Reyer
Facility Name
Hospital Universitario Donostia
City
San Sebastián
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mariano de Blas
Facility Name
Inselspital Bern, Universitätsklinik für Gefässchirurgie
City
Bern
ZIP/Postal Code
3010
Country
Switzerland
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Drosos Kotelis, Prof

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES

We'll reach out to this number within 24 hrs